Corcept Therapeutics Incorporated(CORT) Stock Research - Grey Stern Research

Corcept Therapeutics Incorporated (CORT) Stock Analysis

$35.60 (2.09%)

CORT Financial Performance


Use the table below to view Corcept Therapeutics Incorporated's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $34.87 -
52 Week Low $20.84 -
52 Week High $35.87 -
Market Cap $3.6 Billion 8/23
Gross Margin 98% 2/23
Profit Margin 19% 2/23
EBITDA margin 20% 2/23
Q1 - 2024 Revenue $146.8 Million 2/23
Q1 - 2024 Earnings $27.8 Million 2/23
Q1 - 2024 Free Cash Flow $23.8 Million 2/23
Trailing 4 Quarters Revenue $523.5 Million 2/23
Trailing 4 Quarters Earnings $118.0 Million 2/23
Quarterly Earnings Growth 75% 3/23
Annual Earnings Growth 80% 1/23
Quarterly Revenue Growth 39% 3/23
Annual Revenue Growth 26% 5/23
Cash On Hand $149.8 Million 9/23
Short Term Debt $76,000 21/23
Long Term Debt $0 22/23

Corcept Therapeutics Incorporated Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Corcept Therapeutics Incorporated's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 30.76 1/23
PS 6.93 15/23
PB 6.63 7/23
PC 24.24 10/23
Liabilities to Equity 0.20 9/23
ROA 0.18 1/23
ROE 0.22 4/23
Current Ratio 6.07 13/23
Quick Ratio 3.80 13/23
Long Term Debt to Equity 0.00 17/23
Debt to Equity 0.00 18/23
Burn Rate -5.40 21/23
Cash to Cap 0.04 13/23
CCR 0.86 20/23
EV to EBITDA 117.51 1/23
EV to Revenue 6.65 13/23

Company Details

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

CEO: Dr. Joseph Belanoff

Website: https://www.corcept.com

Address: 149 Commonwealth Dr Menlo Park, CALIFORNIA

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Corcept Therapeutics Incorporated Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Corcept Therapeutics Incorporated. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Insmed Incorporated INSM $12.0 Billion
Halozyme Therapeutics, Inc. HALO $7.2 Billion
Dyne Therapeutics, Inc. DYN $4.4 Billion
Ultragenyx Pharmaceutical Inc. RARE $4.1 Billion
AnaptysBio, Inc. ANAB $1.0 Billion
Cytokinetics, Incorporated CYTK $7.0 Billion
Agios Pharmaceuticals, Inc. AGIO $2.7 Billion
Merrimack Pharmaceuticals, Inc. MACK $224.0 Million
Homology Medicines, Inc. FIXX $3.0 Million
IDEAYA Biosciences, Inc. IDYA $3.6 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
MeiraGTx Holdings plc MGTX $325.4 Million
NextCure, Inc. NXTC $45.9 Million
Keros Therapeutics, Inc. KROS $1.9 Billion
Nuvation Bio Inc. NUVB $926.3 Million
Cerevel Therapeutics Holdings, Inc. CERE $8.1 Billion
Sensei Biotherapeutics, Inc. SNSE $16.6 Million
Edgewise Therapeutics, Inc. EWTX $1.8 Billion
Monte Rosa Therapeutics, Inc. GLUE $285.6 Million
Graphite Bio, Inc. GRPH $185.2 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Erasca, Inc. ERAS $852.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CORT Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 146.8 Million $27.8 Million
Q4 2023 $ 135.4 Million $31.4 Million
Q3 2023 $ 123.6 Million $31.4 Million
Q2 2023 $ 117.7 Million $27.5 Million
Q1 2023 $ 105.7 Million $15.9 Million
Q4 2022 $ 103.1 Million $16.6 Million
Q3 2022 $ 101.7 Million $34.6 Million
Q2 2022 $ 103.4 Million $27.4 Million

View All

CORT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $149.8 Million $655.9 Million $76,000 $547.9 Million
Q4 2023 $135.6 Million $621.5 Million $151,000 $506.7 Million
Q3 2023 $111.8 Million $594.0 Million $225,000 $461.7 Million
Q2 2023 $172.4 Million $524.6 Million $297,000 $421.6 Million
Q1 2023 $465.1 Million $617.8 Million $575,000 $529.6 Million
Q4 2022 $436.6 Million $583.4 Million $1.1 Million $501.8 Million
Q3 2022 $50.2 Million $533.3 Million $1.7 Million $473.4 Million
Q2 2022 $35.3 Million $496.4 Million $2.3 Million $442.3 Million

View All

CORT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $23.8 Million $0 $14.2 Million
Q4 2023 $5.9 Million $0 $23.8 Million
Q3 2023 $52.9 Million -$37,000 -$60.6 Million
Q2 2023 $42.2 Million -$102,000 -$127.6 Million
Q1 2023 $26.0 Million $0 $233.6 Million
Q4 2022 $33.4 Million -$31,000 $16.1 Million
Q3 2022 $33.3 Million -$351,000 $14.9 Million
Q2 2022 $18.0 Million -$19,000 -$26.5 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions